Bio-Techne (TECH) Price & Analysis

Compare

515 Followers

TECH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$46.01 - $80.95

Previous CloseN/A

Volume102.39K

Average Volume (3M)2.16M

Market Cap

$8.28B

Enterprise Value$8.25B

Total Cash (Recent Filing)$140.67M

Total Debt (Recent Filing)$423.50M

Price to Earnings (P/E)114.8

Beta0.93

Next Earnings

Nov 04, 2025

EPS Estimate

0.42

Next Dividend Ex-Date

Aug 18, 2025

Dividend Yield0.61%

Share Statistics

EPS (TTM)0.53

Shares Outstanding156,767,290

10 Day Avg. Volume2,687,521

30 Day Avg. Volume2,164,259

Financial Highlights & Ratios

PEG Ratio-1.64

Price to Book (P/B)5.46

Price to Sales (P/S)9.74

P/FCF Ratio47.83

Enterprise Value/Market Cap1.00

Enterprise Value/Revenue6.83

Enterprise Value/Gross Profit10.36

Enterprise Value/Ebitda26.33

Forecast

1Y Price Target

$63.91

Price Target Upside20.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Financial PerformanceThe financial results showed a slight beat on revenue and profitability metrics were better than expected.

Growth PotentialBio-Techne is considered one of the best-positioned companies to see growth despite uncertainties.

Strategic DivestitureThe recent divestiture of ExoDx allows Bio-Techne to free up capital, improve margins, and invest further in its strategic growth areas.

Bears Say

Management GuidanceManagement's preliminary guidance came as a surprise with lower than expected growth projections due to ongoing policy uncertainties.

Market ReactionManagement's messaging on growth outlook led to shares trading down about 8%.

Policy UncertaintyThere is uncertainty due to policy issues such as NIH funding, pharma tariffs, and most-favored nation pricing, affecting short-term growth projections.

Bio-Techne News

Bio-Techne reports Q4 adjusted EPS 53c, consensus 50c

Reports Q4 revenue $316.96M, consensus $314.7M. “Bio-Techne (TECH) delivered a solid fourth quarter that was in-line with our...

7d ago

TECH

Bio-Techne to divest Exosome Diagnostics business to Mdxhealth

Bio-Techne (TECH) announced an agreement where Mdxhealth (MDXH) will acquire its Exosome Diagnostics business, including the ExoDx Prostate...

8d ago

MDXH

TECH

Bio-Techne price target raised to $58 from $51 at Baird

Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Bio-Techne (TECH) to $58 from $51 and...

13d ago

TECH

Bio-Techne resumed with an Overweight at Stephens

Stephens analyst Steven Etoch resumed coverage of Bio-Techne (TECH) with an Overweight rating and $65 price target The...

23d ago

TECH

Bio-Techne and Spear Bio partner for ultrasensitive biomarker detection

Bio-Techne (TECH) announced a strategic partnership to distribute Spear Bio’s next-generation ultrasensitive immunoassays, enabling the detection of low-abundance...

29d ago

TECH

Strategic Divestiture and Focus on Core Strengths Justify Buy Rating for Bio-Techne

Leerink Partners analyst Puneet Souda has maintained their bullish stance on TECH stock, giving a Buy rating today....

6d ago

TECH

Bio-Techne’s Strong Q4 Performance and Strategic Moves Justify Buy Rating

Bio-Techne, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brandon Couillard from Wells...

7d ago

TECH

Bio-Techne Reports Solid Q4 2025 Results Amid Strategic Shift

Bio-Techne ( ($TECH) ) has released its Q4 earnings. Here is a breakdown of the information Bio-Techne presented...

7d ago

TECH

Bio-Techne’s Earnings Call: Growth Amid Challenges

Bio-Techne (($TECH)) has held its Q4 earnings call. Read on for the main highlights of the call. Bio-Techne’s...

7d ago

TECH

Bio-Techne Divests Exosome Diagnostics to Boost Growth

Bio-Techne ( ($TECH) ) has issued an update. Bio-Techne reported its fourth quarter fiscal 2025 results, highlighting a...

7d ago

TECH

Promising Long-Term Growth for Bio-Techne Amidst Current Challenges: A Buy Recommendation by Kyle Boucher

TD Cowen analyst Kyle Boucher maintained a Buy rating on Bio-Techne today and set a price target of...

14d ago

TECH

Bio-Techne initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Bio-Techne (TECH) with a Buy rating and $65 price target The pullback and...

1M ago

TECH

Bio-Techne: Undervalued Stock with Strong Growth Potential and Margin Expansion Opportunities

Daniel Brennan, an analyst from TD Cowen, has initiated a new Buy rating on Bio-Techne (TECH). Daniel Brennan...

1M ago

TECH

Bio-Techne, USP collaborate to develop monoclonal antibody and gene therapy

Bio-Techne (TECH) announced a distribution agreement with the U.S. Pharmacopeia, or USP, that enables the company to sell...

2M ago

TECH

TECH FAQ

What was Bio-Techne’s price range in the past 12 months?

Bio-Techne lowest stock price was $46.01 and its highest was $80.95 in the past 12 months.

What is Bio-Techne’s market cap?

Bio-Techne’s market cap is $8.28B.

When is Bio-Techne’s upcoming earnings report date?

Bio-Techne’s upcoming earnings report date is Nov 04, 2025 which is in 83 days.

How were Bio-Techne’s earnings last quarter?

Bio-Techne released its earnings results on Aug 06, 2025. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.499 by $0.031.

Is Bio-Techne overvalued?

According to Wall Street analysts Bio-Techne’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bio-Techne pay dividends?

Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.61%. See more information on Bio-Techne dividends here

What is Bio-Techne’s EPS estimate?

Bio-Techne’s EPS estimate is 0.42.

How many shares outstanding does Bio-Techne have?

Bio-Techne has 156,767,290 shares outstanding.

What happened to Bio-Techne’s price movement after its last earnings report?

Bio-Techne reported an EPS of $0.53 in its last earnings report, beating expectations of $0.499. Following the earnings report the stock price went down -8.73%.

Which hedge fund is a major shareholder of Bio-Techne?

Currently, no hedge funds are holding shares in TECH

Bio-Techne Stock Smart Score

Outperform

Fundamentals

Return on Equity

3.68%

Trailing 12-Months

Asset Growth

-9.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bio-Techne

Bio-Techne Corporation (TECH) is a leading developer and manufacturer of high-quality biotechnology products and solutions. The company operates in the life sciences sector, focusing on providing innovative tools and reagents to researchers and clinicians worldwide. Bio-Techne's core offerings include proteins, antibodies, immunoassays, and instruments used in scientific research, diagnostics, and therapeutic development.

Bio-Techne (TECH) Earnings & Revenues

Historic Earnings Reports

TECH Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

Bio-Techne's earnings call highlighted solid organic growth and strategic positioning in core markets, especially in biopharma and cell therapy. However, uncertainties in academic funding, biotech market challenges, and policy-related headwinds create a cautious outlook.View all TECH earnings summaries

TECH Net revenue Breakdown

71.69% Protein Sciences

28.16% Diagnostics and Genomics

0.36% Other

TECH Stock 12 Month Forecast

Average Price Target

$63.91

▲(20.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","82":"$82","55.75":"$55.8","64.5":"$64.5","73.25":"$73.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,55.75,64.5,73.25,82],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.89,56.43692307692308,57.98384615384615,59.53076923076923,61.07769230769231,62.62461538461538,64.17153846153846,65.71846153846154,67.26538461538462,68.8123076923077,70.35923076923078,71.90615384615384,73.45307692307692,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.89,55.58384615384615,56.277692307692305,56.97153846153846,57.66538461538462,58.35923076923077,59.05307692307692,59.746923076923075,60.44076923076923,61.13461538461538,61.82846153846154,62.52230769230769,63.216153846153844,{"y":63.91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.89,54.744615384615386,54.59923076923077,54.45384615384616,54.308461538461536,54.16307692307692,54.01769230769231,53.87230769230769,53.72692307692308,53.581538461538464,53.43615384615384,53.29076923076923,53.145384615384614,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":81.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.87,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >